1999
Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185
Boyer C, Pusztai L, Wiener J, Xu F, Dean G, Bast B, O'Briant K, Greenwald M, DeSombre K, Bast R. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c‐erbB‐2 (HER‐2/neu) gene product p185. International Journal Of Cancer 1999, 82: 525-531. PMID: 10404066, DOI: 10.1002/(sici)1097-0215(19990812)82:4<525::aid-ijc10>3.0.co;2-j.Peer-Reviewed Original ResearchConceptsDifferent epitopesHER-2 receptorBreast cancer cell linesHER-2/neu geneRelative cytotoxic activityCytotoxic activityCancer cell linesEpitope targetsImmunotoxin therapyC-erbBImmunoglobulin isotypesUnconjugated antibodyEffective immunotoxinsExtracellular domainClonogenic assayImmunotoxinEpitope expressionNeu geneCompetitive binding assaysAntibodiesEpitopesAntibody bindingCell linesReceptorsBinding assays
1998
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
Dean G, Pusztai L, Xu F, O'Briant K, DeSombre K, Conaway M, Boyer C, Mendelsohn J, Bast R. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clinical Cancer Research 1998, 4: 2545-50. PMID: 9796989.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsReceptors/cellCancer cellsC-erbBSynergistic cytotoxicityCopies/cellTumor cellsSKOV3 human ovarian cancer cellsHuman ovarian cancer cellsClonogenic tumor cellsCell surface densityBreast cancerRTA immunotoxinsNude miceSame immunotoxinFirst treatmentAnchorage-independent growthAnchorage-dependent growthVivo growthClonogenic cellsImmunotoxinExpression levelsSignificant correlationCell linesNormal cells